Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Solid Sales for Monoclonal Antibodies in Rheumatoid Arthritis Treatment May Prove Biologics Can Overcome the Patent Cliff

By BiotechDaily International staff writers
Posted on 25 Mar 2013
The market for monocloncal antibodies (mAbs) use in the treatment of rheumatoid arthritis (RA) since 2004 has experienced very significant growth, and it is on the threshold of entering a historically extraordinary scenario over the next six years, according to new market research.

According to healthcare market research company GBI Research (New York, NY, USA), eight mAbs are currently approved, half of which count among the top 10 best-selling drugs worldwide, collectively generating over USD 23 billion in sales in 2011. mAbs Remicade is also the blockbusting pharmaceutical product across the entire industry. The approaching patent cliff seems not likely to knock these popular drugs off their position, in a market that is slow to accept new products.

The first three mAbs to be approved to treat RA—Humira, Remicade, and Enbrel—have consistently dominated RA drug sales since their market entry, in spite of the approval of debatably more effective mAb products since then. GBI analyst Dominic Trewartha stated, “Physicians are likely to exercise great caution when prescribing biologics, in part due to their potentially serious side effects. Rheumatologists in general are also quite conservative in their treatment patterns, which could explain why Remicade, Humira and Enbrel are doing so well, being the first mAbs approved for RA. In contrast, biosimilars are less likely to be prescribed. For this reason, the growth of the global market is expected to continue in spite of the impending patent expiry of three of the four top-selling RA mAbs in the US.”

The RA mAbs market in the United States, Japan, Germany, France, the United Kingdom, Spain, and Italy is expected to grow from USD 11.5 billion in 2011 to USD 15.7 billion by 2018. Mr. He continued, “None of the potential market entrants appear to offer any significant improvements to existing medications, and thus will not dramatically affect the market size in the coming years, leaving Remicade, Humira, and Enbrel to maintain their top-selling RA mAbs status.”

The costs and problems tied to bringing biosimilars to the market is also expected to restrict the number of biosimilars and their impact on drug pricing for RA mAbs, estimated to be as low as 10%.

GBI Research is a provider of business intelligence reports, providing data and forecasts based on the insights of key industry experts with the latest emerging trends.

Related Links:

GBI Research



comments powered by Disqus

Channels

Genomics/Proteomics

view channel

New Program Encourages Wide Distribution of Genomic Data

A new data sharing program allows genomics researchers and practitioners to analyze, visualize, and share raw sequence data for individual patients or across populations straight from a local browser. The sequencing revolution is providing the raw data required to identify the genetic variants underlying rare diseases... Read more

Drug Discovery

view channel
Image: The nano-cocoon drug delivery system is biocompatible, specifically targets cancer cells, can carry a large drug load, and releases the drugs very quickly once inside the cancer cell. Ligands on the surface of the \"cocoon\" trick cancer cells into consuming it. Enzymes (the “worms\" in this image) inside the cocoon are unleashed once inside the cell, destroying the cocoon and releasing anticancer drugs into the cell (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Novel Anticancer Drug Delivery System Utilizes DNA-Based Nanocapsules

A novel DNA-based drug delivery system minimizes damage to normal tissues by utilizing the acidic microenvironment inside cancer cells to trigger the directed release of the anticancer drug doxorubicin (DOX).... Read more

Lab Technologies

view channel

Experimental Physicists Find Clues into How Radiotherapy Kills Cancer Cells

A new discovery in experimental physics has implications for a better determination of the process in which radiotherapy destroys cancer cells. Dr. Jason Greenwood from Queen’s University Belfast (Ireland) Center for Plasma Physics collaborated with scientists from Italy and Spain on the work on electrons, and published... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.